Zimbuck – Your Market. Your Community.
BREAKING: Legend Biotech swings to a profit as CARVYKTI sales surge 36%.

The cell-therapy maker reported Q3 CARVYKTI net trade sales of about $710 million, up 36% year over year, with U.S. sales up 19% and ex-U.S. sales up 86%. Collaboration revenue rose to $353.2 million from $261.8 million a year earlier.

Adjusted net income came in at $55.6 million, versus an adjusted net loss of $18.7 million a year ago, and Legend ended the quarter with about $853 million in cash and time deposits.

Sources: Legend Biotech Q3 2026 results (Globe Newswire, Nov 10, 2026)

#LegendBiotech #LEGN #Biotech #Earnings #Stocks #Markets
Like
Love
Wow
9
141 Views